EA202192596A1 - Противораковая комбинированная терапия - Google Patents

Противораковая комбинированная терапия

Info

Publication number
EA202192596A1
EA202192596A1 EA202192596A EA202192596A EA202192596A1 EA 202192596 A1 EA202192596 A1 EA 202192596A1 EA 202192596 A EA202192596 A EA 202192596A EA 202192596 A EA202192596 A EA 202192596A EA 202192596 A1 EA202192596 A1 EA 202192596A1
Authority
EA
Eurasian Patent Office
Prior art keywords
combination therapy
cancer combination
cancer
lrp6
lrp5
Prior art date
Application number
EA202192596A
Other languages
English (en)
Inventor
Виттория Цинцалла
Барбара Дробитс-Хандль
Маркус Йоханн Бауэр
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA202192596A1 publication Critical patent/EA202192596A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

В изобретении описаны противораковые терапии, включающие применение полипептида, способного специфически связываться с LRP5 и LRP6, в комбинации с антителом к PD1, каждый из них описан в настоящем изобретении.
EA202192596A 2019-03-29 2020-03-26 Противораковая комбинированная терапия EA202192596A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19166375 2019-03-29
PCT/EP2020/058513 WO2020200997A1 (en) 2019-03-29 2020-03-26 Anticancer combination therapy

Publications (1)

Publication Number Publication Date
EA202192596A1 true EA202192596A1 (ru) 2022-02-14

Family

ID=66041332

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192596A EA202192596A1 (ru) 2019-03-29 2020-03-26 Противораковая комбинированная терапия

Country Status (14)

Country Link
US (1) US20200308276A1 (ru)
EP (1) EP3947455A1 (ru)
JP (1) JP2022527097A (ru)
KR (1) KR20210144736A (ru)
CN (1) CN113661178A (ru)
AU (1) AU2020250810A1 (ru)
BR (1) BR112021016520A2 (ru)
CA (1) CA3130663A1 (ru)
CL (1) CL2021002190A1 (ru)
EA (1) EA202192596A1 (ru)
IL (1) IL286700A (ru)
MX (1) MX2021011854A (ru)
TW (1) TW202108615A (ru)
WO (1) WO2020200997A1 (ru)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1814917A2 (en) 2004-10-13 2007-08-08 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
EP2949668B1 (en) 2005-05-18 2019-08-14 Ablynx N.V. Improved nanobodies tm against tumor necrosis factor-alpha
DE112009000507T5 (de) 2008-03-05 2011-02-10 Ablynx Nv Neue Antigen-bindende Dimerkomplexe, Verfahren zu ihrer Herstellung und ihre Verwendung
NZ602040A (en) * 2010-03-24 2014-12-24 Genentech Inc Anti-lrp6 antibodies
ES2659406T3 (es) * 2010-05-06 2018-03-15 Novartis Ag Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6)
US8790650B2 (en) * 2011-04-28 2014-07-29 Vanderbilt University Methods of using an antibody to inhibit WNT-mediated cardiac remodeling
ES2821099T3 (es) 2015-12-04 2021-04-23 Boehringer Ingelheim Int Gmbh & Co Kg Polipéptidos biparatópicos antagonistas de la señalización WNT en células tumorales
WO2020080941A1 (en) * 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies

Also Published As

Publication number Publication date
CA3130663A1 (en) 2020-10-08
EP3947455A1 (en) 2022-02-09
TW202108615A (zh) 2021-03-01
MX2021011854A (es) 2021-10-22
CN113661178A (zh) 2021-11-16
AU2020250810A1 (en) 2021-09-02
BR112021016520A2 (pt) 2021-10-26
CL2021002190A1 (es) 2022-04-29
IL286700A (en) 2021-10-31
KR20210144736A (ko) 2021-11-30
JP2022527097A (ja) 2022-05-30
WO2020200997A1 (en) 2020-10-08
US20200308276A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
EA201891589A1 (ru) Условно активные гетеродимерные полипептиды и способы их применения
MX2021003393A (es) Proteinas de fijacion a sirp alfa y metodos de uso de estas.
PH12018502182A1 (en) Trispecific and/or trivalent binding proteins
EA201991514A1 (ru) Антитела, которые специфически связываются с ил-15, и их применение
AU2019255744A8 (en) IL-15/IL-15Ra heterodimeric Fc fusion proteins and uses thereof
BR112019005964A2 (pt) proteínas de fusão imunomoduladoras
EA202190542A1 (ru) Сконструированные биспецифические белки
EA201792572A1 (ru) Антитела к ox40 и их применение
EA201692459A1 (ru) Антитела к индуцируемому глюкокортикоидами рецептору фактора некроза опухолей (gitr) и их применения
UY35964A (es) Anticuerpos humanos para pd?1
PH12019502763A1 (en) Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
CO6781527A2 (es) Proteínas de unión de tipo anticuerpo con región variable dual que tienen orientación de la región de unión con entrecruzamiento
MX2020009861A (es) Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos.
EA201991879A1 (ru) Варианты полипептидов и их применение
EA201992281A1 (ru) Связывающие молекулы, специфично связывающиеся с тау-белком
EA202091054A1 (ru) Слитые молекулы на основе антитела против pd-l1 и ил-7
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
EA202190235A1 (ru) Антитела к cd33 и способы их применения
EA201990822A1 (ru) Иммуномодулирующие слитые белки
BR112017023785A2 (pt) polipeptídeos do fator de von willebrand truncados para tratar hemofilia
MX2021001703A (es) Polipeptidos de union a ox40 y sus usos.
MX2021005150A (es) Moleculas de anticuerpos anti tnfr2 antagonistas novedosas.
MX2019005874A (es) Administracion intratecal de virus recombinante adeno-asociado que codifica la proteina 2 que une metilo-cpg.
EA202192596A1 (ru) Противораковая комбинированная терапия